INFUSYSTEM HOLDINGS, INC (INFU) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 3.54%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 3.54% | Share-based compensation / revenue. Period ending 2026-06-30. $5.07M ÷ $143.34M × 100 ≈ 3.54% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 143.34M USD | |
| Stock-based compensation | 5.07M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 13.27M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $143.34M | $5.07M | $13.27M | (m) | (m) | 3.54% | (m) | (m) |
| 2026-03-31 | (m) | $142.40M | $4.49M | $12.89M | (m) | (m) | 3.15% | (m) | (m) |
| 2025-12-31 | (m) | $143.44M | $4.36M | $11.92M | (m) | (m) | 3.04% | (m) | (m) |
| 2025-09-30 | (m) | $141.05M | $4.28M | $10.82M | (m) | (m) | 3.03% | (m) | (m) |
| 2025-06-30 | (m) | $139.89M | $4.17M | $10.28M | (m) | (m) | 2.98% | (m) | (m) |
| 2025-03-31 | (m) | $137.58M | $4.51M | $8.35M | (m) | (m) | 3.28% | (m) | (m) |
| 2024-12-31 | (m) | $134.86M | $4.46M | $6.89M | (m) | (m) | 3.31% | (m) | (m) |
| 2024-09-30 | (m) | $132.78M | $4.55M | $5.53M | (m) | (m) | 3.43% | (m) | (m) |
| 2024-06-30 | (m) | $129.37M | $4.39M | $3.96M | (m) | (m) | 3.40% | (m) | (m) |
| 2024-03-31 | (m) | $127.41M | $4.41M | $3.35M | $2.14M | (m) | 3.46% | 1.56× | Reported |
| 2023-12-31 | (m) | $125.78M | $4.07M | $4.09M | $2.17M | (m) | 3.24% | 1.88× | Reported |
| 2023-09-30 | (m) | $122.84M | $3.39M | $3.87M | $2.09M | (m) | 2.76% | 1.85× | Reported |
| 2023-06-30 | (m) | $118.21M | $3.39M | $3.11M | $1.92M | (m) | 2.87% | 1.63× | Reported |
| 2023-03-31 | (m) | $113.52M | $3.50M | $2.07M | $1.61M | (m) | 3.08% | 1.29× | Reported |
| 2022-12-31 | (m) | $109.91M | $3.83M | $1.65M | $1.40M | (m) | 3.48% | 1.18× | Reported |
| 2022-09-30 | (m) | $107.60M | $4.68M | $2.23M | $1.44M | (m) | 4.35% | 1.54× | Reported |
| 2022-06-30 | (m) | $106.89M | $5.57M | $933.00K | $1.33M | (m) | 5.21% | 0.70× | Reported |
| 2022-03-31 | (m) | $104.68M | $5.82M | $1.42M | $1.33M | (m) | 5.56% | 1.07× | Reported |
| 2021-12-31 | (m) | $102.38M | $6.40M | $2.82M | $1.38M | (m) | 6.26% | 2.05× | Reported |
| 2021-09-30 | (m) | $100.57M | $6.35M | $2.25M | $1.15M | (m) | 6.31% | 1.97× | Reported |
| 2021-06-30 | (m) | $99.13M | $5.05M | $5.86M | $1.16M | (m) | 5.10% | 5.05× | Reported |
| 2021-03-31 | (m) | $100.30M | $4.04M | $9.67M | $1.17M | (m) | 4.03% | 8.23× | Reported |
| 2020-12-31 | (m) | $97.39M | $2.61M | $8.83M | $1.25M | (m) | 2.68% | 7.03× | Reported |
| 2020-09-30 | (m) | $94.39M | $1.44M | $9.10M | $1.49M | (m) | 1.52% | 6.13× | Reported |
| 2020-06-30 | (m) | $90.75M | $1.03M | $7.51M | $1.69M | (m) | 1.13% | 4.44× | Reported |
| 2020-03-31 | (m) | $84.47M | (m) | $3.98M | $1.85M | (m) | (m) | 2.15× | Reported |
| 2019-12-31 | (m) | $81.11M | $997.00K | $3.52M | $1.90M | (m) | 1.23% | 1.85× | Reported |
| 2019-09-30 | (m) | $76.97M | (m) | $2.34M | $1.88M | (m) | (m) | 1.25× | Reported |
| 2019-06-30 | (m) | $72.16M | (m) | $582.00K | $1.76M | (m) | (m) | 0.33× | Reported |
| 2019-03-31 | (m) | $68.85M | (m) | $-593.00K | $1.56M | (m) | (m) | -0.38× | Reported |
| 2018-12-31 | (m) | $67.14M | $957.00K | $415.00K | $1.42M | (m) | 1.43% | 0.29× | Reported |
| 2018-09-30 | (m) | $68.47M | (m) | $-1.02M | $1.30M | (m) | (m) | -0.79× | Reported |
| 2018-06-30 | (m) | $69.38M | (m) | $-367.00K | $1.28M | (m) | (m) | -0.29× | Reported |
| 2018-03-31 | (m) | $69.91M | (m) | $-1.25M | $1.32M | (m) | (m) | -0.95× | Reported |
| 2017-12-31 | (m) | $71.08M | $682.00K | $-3.81M | $1.33M | (m) | 0.96% | -2.86× | Reported |
| 2017-09-30 | (m) | $69.04M | (m) | $-2.96M | $1.34M | (m) | (m) | -2.20× | Reported |
| 2017-06-30 | (m) | $68.68M | (m) | $-2.94M | $1.37M | (m) | (m) | -2.14× | Reported |
| 2017-03-31 | (m) | $69.86M | (m) | $-1.41M | $1.37M | (m) | (m) | -1.03× | Reported |
| 2016-12-31 | (m) | $70.50M | $462.00K | $974.00K | $1.34M | (m) | 0.66% | 0.72× | Reported |
| 2016-09-30 | (m) | $72.39M | (m) | $3.92M | $1.32M | (m) | (m) | 2.96× | Reported |
| 2016-06-30 | (m) | $76.34M | (m) | $8.54M | $1.28M | (m) | (m) | 6.68× | Reported |
| 2016-03-31 | (m) | $74.44M | (m) | $8.48M | $1.34M | (m) | (m) | 6.33× | Reported |
| 2015-12-31 | (m) | $72.13M | $996.00K | $8.86M | $1.71M | (m) | 1.38% | 5.20× | Reported |
| 2015-09-30 | (m) | $68.85M | (m) | $8.35M | $2.18M | (m) | (m) | 3.84× | Reported |
| 2015-06-30 | (m) | $66.77M | (m) | $8.09M | $2.59M | (m) | (m) | 3.12× | Reported |
| 2015-03-31 | (m) | $65.97M | (m) | $9.11M | $2.98M | (m) | (m) | 3.06× | Reported |
| 2014-12-31 | (m) | $66.49M | $576.00K | $9.33M | $3.13M | (m) | 0.87% | 2.98× | Reported |
| 2014-09-30 | (m) | $67.40M | (m) | $9.02M | $3.22M | (m) | (m) | 2.80× | Reported |
| 2014-06-30 | (m) | $66.53M | (m) | $8.50M | $3.30M | (m) | (m) | 2.57× | Reported |
| 2014-03-31 | (m) | $64.82M | (m) | $7.02M | $3.45M | (m) | (m) | 2.03× | Reported |
| 2013-12-31 | (m) | $62.28M | $1.12M | $5.90M | $3.50M | (m) | 1.80% | 1.69× | Reported |
| 2013-09-30 | (m) | $61.34M | (m) | $5.00M | $3.74M | (m) | (m) | 1.34× | Reported |
| 2013-06-30 | (m) | $59.77M | (m) | $4.00M | $3.87M | (m) | (m) | 1.03× | Reported |
| 2013-03-31 | (m) | $59.18M | (m) | $3.17M | $3.61M | (m) | (m) | 0.88× | Reported |
| 2012-12-31 | (m) | $58.83M | $964.00K | $2.00M | $3.34M | (m) | 1.64% | 0.60× | Reported |
| 2012-09-30 | (m) | $56.64M | $775.00K | $-260.00K | $2.78M | (m) | 1.37% | -0.09× | Reported |
| 2012-06-30 | (m) | $56.97M | $993.00K | $-23.68M | $2.35M | (m) | 1.74% | -10.07× | Reported |
| 2012-03-31 | (m) | $56.03M | $1.28M | $-67.10M | $2.25M | (m) | 2.28% | -29.78× | Reported |
| 2011-12-31 | (m) | $54.64M | $1.19M | $-66.36M | $2.19M | (m) | 2.17% | -30.26× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $47.23M | $3.86M | $-938.00K | $3.35M | (m) | 8.17% | -0.28× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $38.96M | $753.00K | $5.33M | $3.50M | (m) | 1.93% | 1.52× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Profound Medical Corp. (PROF) | $0.206B | -7.37 |